Global Narcolepsy Therapeutics Market [By Product (Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, and Tricyclic Antidepressants); By Type (Cataplexy, Narcolepsy without Cataplexy, and Secondary Narcolepsy); and By Regions]: Market size & Forecast, 2018 – 2025

Report Summary

The global narcolepsy therapeutics market was estimated at USD 1348.15 Million in 2017 and is anticipated to gain significant traction over coming years.

Narcolepsy is a chronic nerve disease which is associated with sleep paralysis, hypnagogic hallucinations, Excessive Daytime Sleepiness (EDS), fragmented night sleep, and cataplexy. Narcolepsy is the brain incapability to control sleep-wake phases. The sleep attack can befall during any activity such as while eating, playing, during the conversation or driving. Individuals with such disorder have robust impulse to sleep and have a lack of energy. Narcolepsy generally triggers owing to lack of brain chemical known as hypocretin, inherited conditions, mental illness, hormonal changes, immune-system dysfunction, infections, trauma or stress. Approximately 10% of people having narcolepsy with cataplexy partake a genetic tendency. Narcolepsy can arise in both women or men at any age. Such disorders typically occur in the early twenties and last all throughout the entire life. Narcolepsy syndrome is generally confused with insomnia. Nevertheless, people with narcolepsy experience normal life, yet through the appropriate diagnosis and therapies, the narcolepsy can be controlled.

The global Narcolepsy Therapeutics Market is majorly driven by an incidence of several sleep syndromes. According to the Narcolepsy Networks, Narcolepsy affects an estimated 1 in every 2,000 people in the U.S. That is 200,000 Americans, and around 3 million of a global population. In addition, increasing consciousness regarding the disease and growing demand for advanced therapeutics and diagnostics are another factors expected to boost the market growth. Furthermore, growing demands for appropriate treatment of the disorder followed by growing R&D activities are anticipated to boost the narcolepsy therapeutics market growth.

However, lack of consciousness and lower healthcare spending within the middle and low-income economies are the anticipated to hinder the global narcolepsy market during the forecast period.

细分分析

The global Narcolepsy Therapeutics Market is segmented on the basis of product, type, and geography.

On the basis of product, the global Narcolepsy Therapeutics Market is segmented into Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, and Tricyclic Antidepressants. In 2017, Sodium oxybate was estimated to dominate the market segment. The dominance is due to the presence of favorable reimbursement guidelines, the high cost of this drug, and the increasing awareness levels relating to diagnosis & associated treatments of the disease.

在类型的基础上，全球性肿瘤术治疗性市场被分段为Narclepsy，鼻腔梗死，没有毒物，患有次要的鼻腔。2017年，据估计，与卡录分组的鼻腔梗死占据了市场增长。主导地位归因于患者患者的主要迹象的发育率越来越多。

区域分析

就地理而言，欧洲估计占据全球性嗜病治疗市场。主导地位主要归因于既定的医疗保健组织，崛起的研发倡议，为扩大新药，患有这种疾病的人的高发病率。乐动娱乐官网然而，亚太地区预计将在预测期间占据全球性嗜病治疗市场。可支配收入增长，增加生物技术和制药部门的投资，经济发展，支持性政府举措以及对适当疗法的人们的认识，是预期的因素，预计将在亚太地区大大提振鼻神病疗法市场。

竞争格局

Major firms are focusing on small firms with a working methodology of securing the end goal to manage position in the market and are associated with mergers and acquisitions, key joint efforts, and novel item advancement to pick up profit share in the business. Some major key players in global Narcolepsy Therapeutics Market includes Addrenex Pharmaceuticals, Inc., Arena Pharmaceuticals, Inc., BIOPROJET, Cephalon, Inc., Evotec AG, Graymark Healthcare, Inc., Hypnion, Inc., Jazz Pharmaceuticals, Inc., Ligand Pharmaceuticals, Inc., and Teva Pharmaceutical Industries Ltd. among others.